Summary
The provided AI statements concern FDA Orange Book exclusivity/patent linkage and generic approval timing, but the supplied prescribing information excerpts contain no Orange Book exclusivity, exclusivity dates, or patent/approval timing statements; therefore these claims are unsupported by the provided labeling.
Category Scores
Accurate Statements
Unsupported Statements
Pemetrexed has FDA Orange Book exclusivity protections tied to the original New Drug Application (NDA) listed in the Orange Book.
No Orange Book exclusivity concepts, NDA tie, or any exclusivity/protection statements are present in the supplied prescribing information excerpts.
The exact Orange Book exclusivity date for pemetrexed depends on the specific Orange Book listing, including dosage form and strength and the proprietary name tied to the NDA.
The provided excerpts do not mention Orange Book listings, exclusivity dates, dosage form/strength/proprietary name dependence, or any guidance on how exclusivity dates are determined.
The precise exclusivity expiry date can be found by looking up the specific pemetrexed entry in the FDA Orange Book and reading the "Exclusivity" section for that listing.
The provided excerpts do not reference FDA Orange Book, any 'Exclusivity' section, or how to obtain exclusivity expiry dates.
The Orange Book exclusivity date determines when the FDA can reference exclusivity protections for new approvals that rely on the same active ingredient and reference listed drug.
The provided excerpts do not describe FDA reference/approval behavior related to Orange Book exclusivity.
After Orange Book exclusivity ends, patents can still block generic or biosimilar approvals.
The provided excerpts do not discuss patents, generics/biosimilars, or approval blocking mechanisms.
Orange Book exclusivity date differs from patent expiration date listed on the same Orange Book entry.
The provided excerpts do not mention Orange Book exclusivity dates or patent expiration dates or their relationship.
Contradictions
Important Omissions
No label-supported statement addressing FDA Orange Book exclusivity dates, 'Exclusivity' section lookup, or patent/generic/biosimilar approval timing. This is a material mismatch because the user's statements rely entirely on non-label Orange Book concepts.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The statements are administrative/regulatory assertions not supported by the supplied prescribing information excerpts. While not directly dosing-related, unsupported claims about approval timing/exclusivity could mislead regulatory or access-related decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All provided claims concern Orange Book exclusivity and patent/generic approval timing and are not present in the supplied PEMFEXY prescribing information excerpts.
Suggested Improvement
Limit the answer to information explicitly contained in the provided prescribing information (e.g., indications, contraindications, dosing, and safety/interaction guidance), or provide a label excerpt that contains Orange Book/exclusivity-related language before making those claims.